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This paper identifies and analyses the motivations, capability handicaps and 
responses of a sample of Indian pharmaceutical firms in the early phase of 
internationalization. It distinguishes between the experiences of two types of 
internationalisers –initial internationalisers and later internationalisers - in the 
industry.  It argues that the initial internationalisers face several discontinuities vis-a-
vis the experience of meeting the needs of domestic market. They need to cultivate 
new capabilities by leveraging on whatever is available within the firms and the 
external environment. Their capability to cultivate depends on their internal 
processes to absorb the new experiences. The later internationalisers do not 
experience these handicaps. They can benefit from the industry experience and 
congregate capabilities to move faster.  Their capability to congregate depends on the 
initial endowments of the founders. Based on its findings, the paper outlines scope for 
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Motivations, Capability Handicaps and Firm Responses in the  
Early Phase of Internationalization from Emerging Economies:   






1.1 From Dependence to Independence and Internationalization  
 
From being an import dependent industry in the 1950s, the Indian pharmaceutical 
industry has achieved self-sufficiency and gained global recognition as a producer of low 
cost and high quality bulk drugs and formulations
1. It has emerged as the fourth largest, in 
volume terms and thirteenth largest, in value terms ($8.5 Billion), pharmaceuticals 
industry in the world. It is ranked among the top 20 pharmaceutical exporters in the 
world. Exports during 1990-94, 1995-99 and 2000-04 grew at 13%, 23% and 45% 
respectively
2. Leading Indian pharmaceutical companies have their presence in more than 
70 nations, including United States of America.  India has the largest number (60) of 
United States Food and Drugs Administration (USFDA) approved plants outside USA 
and a large number (126) of Drug master File (DMF) and product registrations
3.
 Indian 
companies have licensing deals with MNC’s for New Chemical Entity (NCE) and New 
Drug Delivery System (NDDS), contract manufacturing, Research and Development (R 
& D) alliances and alliances for clinical trials. Leading companies like Cadila Healthcare 
Limited, Cipla Limited, Dr. Reddy’s Laboratory Limited, Lupin Limited, Matrix 
Laboratories Limited, Ranbaxy Laboratories Limited, Torrent Pharmaceuticals Limited 
and Wockhardt Limited have been recognized at international levels.  
 
1.2 The Foundation 
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The foundation for this achievement was laid by the establishment of Indian Drugs and 
Pharmaceutical Ltd. (IDPL) in 1954 and Hindustan Antibiotics Ltd. (HAL) in 1961 by the 
Government of India to manufacture bulk drugs. These public sector units helped to grow 
the industry through spillover of knowledge and talent (Pradhan, 2006).  The introduction 
of the Indian Patent Act (IPA) that recognized only process patents and not product 
patents in 1970 facilitated the setting up of formulation units on the strength of process 
innovations and reverse engineering. The next milestone in Indian pharmaceutical 
 
1 www.pharmainfo.net/magazine 
2 Ciionline.org/industrial sector-Drugs & Pharmaceuticals/ 
3 Deccan Herald: “Drugs Patent: A Viagra for Indian Pharmaceutical Industry”, April 4, 2005 
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industry was the introduction of New Drug Policy (NDP) of 1978, which allowed Foreign 
Direct Investment (FDI) up to 74% in high technology drugs. It forced the Multinational 
Corporations (MNCs) in the sector to start manufacturing bulk drugs in India, if they 
wished to sell formulations in the local market. The talent flow from MNCs enabled the 
Indian companies to develop capabilities in bulk drugs also. The next milestone was 
harnessing opportunities abroad. Indian companies developed off patent drugs and 
entered international markets. Later they even acquired pharmaceutical companies 
abroad. By 2009 many blockbuster drugs would go off patent that would accord 
opportunities to supply bulk drugs and formulations to advanced markets.  
 
1.3 The Questions 
 
We need to understand and analyse the above experience and draw lessons in the 
internationalization of knowledge intensive industries in the emerging economies, 
focusing specially on the early phase. The emerging economy firms typically hail from 
economies with underdeveloped institutions and market intermediaries that add to the 
transaction costs of accessing resources and doing business in general (Khanna and 
Palepu, 1997). The challenges in internationalisation in terms of overcoming capability 
handicaps as late movers and competing with firms from developed economies that have 
better access to financial capital, advanced technologies and managerial capabilities have 
been well documented. (Lall, 1983; Wells, 1993; Guillen, 2000; and Khanna and Palepu, 
2006). Chittor and Ray (2007) noted that the Indian pharmaceutical firms followed 
different internationalization strategies though they were in the same geographical, 
economic and industry context. They raised the following questions: 
  
(i)  Why do different firms follow different internationalization strategies / path / 
trajectories even though they are subject to identical environments? 
(ii)  Is it the firm level factors that affect the internationalization strategies or is it 
environmental factors?  
(iii)  What are the paths of internationalization? 
 
In the context of these questions the paper focuses on the early phase of 
internationalization of the Indian pharmaceutical industry.  It argues that the early phase 
marks several discontinuities for the firms engaged in meeting the needs of domestic 
market. It has its expectations and anxieties arising from the motivations to 
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internationalize and capability handicaps that delay the realization of motivations. How 
firms respond to them decides the trajectory of subsequent developments in 
internationalization. The paper draws insights from in depth studies of six pharmaceutical 
companies and a quick study of the seventh one. It identifies the motives of the firms, 
barriers for entry and entry facilitators during early phase internationalization. It also 
identifies the sequence in which the international markets were approached and products 
offered. It analyses the key capabilities required and developed during this phase. Based 
on the insights it outlines the scope for further research in capability building for 
internationalization of emerging economy firms. 
 
2.  Insights from Literature  
  
2.1 Stages in Internationalization 
 
Crick (1995), Johanson and Vahlne (1977); Johanson and Wiedersheim-Paul (1975); 
Anderson (1993); Bilkey and Tesar (1977); Leonidou and Katsikeas (1996); Root, (1987) 
conceptualized the stage theory of internationalisation. According to them 
internationalization takes place in stages i.e. firms start with exports as an entry strategy 
and move to 100% subsidiary abroad. The intermediate stages are licensing and joint 
venture. The firms are identified as non-exporters, export intenders, sporadic exporters 
and regular exporters. Other researchers (Sullivan and Bauerschmidt, 1990; Welch and 
Loustarinen, 1988; Barney, 1991; Oviatt and Mc Dougall (1994) have argued that firms 
need not follow the stages to internationalize their business They could emerge as a 
global firm from day one. Knowledge for initiating exports and top management 
commitment, (Palumbo, 1996), superior products, service quality and technology 
(Westhead, Wright and Ucbasaran 2004)) are identified as the facilitators of 
internationalization.  It has also been found that entrepreneurial management, flexibility 
and responsiveness to change and proclivities towards technological and financial 
innovations enable firms to overcome resource barriers in the early stage of 
internationalization (Karagozoglu and Lindell, 1998). The progress of internationalization 
is affected by factors like organization’s capacity in terms of people, structure, finance, 
firm specific intangible assets, technological level of the firm, size of the firm, the age of 
CEO (Chief Executive Officer), and planning and the perceived dynamism in the firm’s 
environment (Anderson, Gabrielsson and Wictor 2004). Researchers have studied 
dimensions of early phase of internationalization in isolation along dimensions like 
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markets entered, products offered, market entry strategy and motives of 
internationalization. The factors identified for selection and developments of markets in 
early phase have been psychic and geographical distance from home market, culture, 
local skills, social and political stability, host government policy and previous experience 
with the country (Child, Sek and Christine 2002). It is contended that firms offer products 
similar to the products offered in local markets and use exports as market entry strategy 
(Chetty, 1999). Motives have been to follow their clients who spread activities 
internationally, expansion of their own activities (Post, Widerom and Douma, 1998; 
Sluyterman, 1998) and responding to opportunities in international markets (Karagozoglu 
and Lindell, 1998).  
 
2.2 Internationalization of firms from Emerging markets: 
 
Emerging markets are countries experiencing rapid economic development, with their 
economic institutions also undergoing rapid adaptation to free market ideologies (Arnold 
and Quelch, 1998; Hoskisson et al., 2000).  A decade before, these markets were, in most 
instances, characterized by a lack of international competition and a domination of state-
owned firms in the economy.  The customers had limited choices, and competition was 
generally low in most product segments (Aulakh et al., 2000). Within a decade these 
markets underwent a radical change, with increasing globalization and openness to 
international competition: Foreign competition and newer opportunities brought by 
globalization have led many firms in emerging markets to seek internationalization. The 
changes made some firms more ambitious than others. They sought to harness growth 
opportunities abroad. 
  
Despite their motivation to seek international markets, firms from these markets face 
several constraints in pursuit of their international expansion strategy. First, since they 
were located in environments that had previously offered institutional protection from 
foreign competition to local firms, emerging market firms have developed products and 
services independently of international markets, making the transition process very 
difficult (Eriksson et al., 1997). Second, unlike established multinational firms (MNCs), 
the competitive advantages of these firms are based on price competition rather than on 
leading edge technology or product differentiation (Kumar and McLeod, 1981; Lall, 
1983; Wells, 1983). Therefore, while these firms possess some resources, they are not of 
the kind that would lead to monopolistic advantages in international markets. Third, since 
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these firms’ focus was on low-cost products, they operated as suppliers to other 
manufacturers or depended on third-party distributors to distribute their products. As a 
result, they lack requisite international experience compared with established firms in 
developed countries (Vernon-Wortzel and Wortzel, 1988; Brouthers et al., 2005). Finally 
these firms are relatively small in size compared with developed country rivals, and are 
usually handicapped by limited organizational resources. In addition to these handicaps, 
they also face the costs and perils of international operations due to liabilities of 
foreignness (Zaheer, 1995). Therefore there is a need for these firms to learn and develop 
the capabilities to operate abroad (Barkema and Vermeulen, 1998). Questions to be 
answered are what are the capabilities required for internationalization of firms from 
emerging market to overcome the barriers mentioned above and how do they develop 
theses capabilities?  The preparation to respond happens in the early phase of 
internationalization. The next section presents the profile of the firms being studied by us 
to respond to the questions relating to motivation, entry sequence, capability handicaps 
and strategies for overcoming the handicaps.  
 
 
3. Firm Profiles 
 
Out of the seven firms studied, two firms, SLC and CRM, were later internationalizers 
and the rest were early internationalizers in the pharmaceutical industry. The later 
internationalisers embarked on their internationalization almost immediately after they 
were set up in the post liberalization era. The others focused on domestic market for an 
extended period. The internationalizing experiences of these firms were profiled through 
interaction with their top and senior executives of the company. Special focus was on 
interacting with executives associated with the early phase of internationalization. Data 
was collected during February to August 2006. Additional data on the firms was gathered 
from websites, promotional brochures, news letters, business reports, news articles and 
balance sheets of the selected companies. The qualitative data was classified and 
tabulated for analysis. The variables studied were motives of the firms, barriers for entry, 
facilitators, timings of entry, sequence of markets entered, products offered and market 
entry strategy in early phase of internationalization. Capabilities required and developed 
during the early phase of internationalization were also identified. Pattern matching 
analysis helped in identifying aspects of similarities and differences. A grouping of the 
firms is given in table 1.  
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Table 1 Grouping of Sample Firms 
Firms  Motivation  Outcome 
XBR, 
PTR 
Were well established in local market, moved 
aggressively, explored international markets 
on their own 
Highly successful 
internationalization having 
presence in all market segments 
SLC 
SLC moved faster as the 
promoters had previous 
internationalization experience 
CRM 
Both the firms were established after 1990s. 
One of the firm i.e. SLC had previous 
experience therefore was aggressive and 
moved faster than the other one i.e. CRM 
which had cautious approach. SLC ventured 
on its own while CRM recruited an 
experienced hand 
CRM adopted an incremental 




Mainly focused on domestic market. Low 
level of aggressiveness and used experienced 
hands 
Moderate level of success as 
partial interest in 
internationalization, well 
established in local market 
LSA 
Diversified firm, high level of intentionality 
but lacked planning. Used consultants to gain 
insights 
Repeated failures but had high 
intentions, got success at the end 
 
Firms with high level of intentionality are XBR, PTR, SLC and CRM. They are either 
highly successful or growing and successful firms. Firms XBR and PTR got early mover 
advantage but at the same time they had to overcome barrier by venturing on their own 
through trial and error. SLC’s management had previous exposure to internationalization 
through their association with earlier firm. CRM could get experienced hands from the 
market. LSA also had high level of intentions but they lacked planning for 
internationalization therefore it failed repeatedly. It also had cushion in terms of major 
revenues from other product line. Pharmaceutical constituted negligible proportion (less 
than 0.5%) of their sales. Other firms LDC and PEL had domestic business as their main 
focus. They also had low level of intentionality which restricted them to be aggressive for 
internationalization. Therefore they could achieve moderate level of success.  
 
The firms studied reflect diversity in terms of age, gap between the year of incorporation 
and initiation of export, first market for entry and infrastructure facilities to cater to 
international markets. The oldest firm was established in 1946. It was also the last to start 
exporting. The youngest firm set up in 1998, ventured out in the first year itself. The 
markets entered and sequence of entry has been different for different firms. The product 
facilitating entry in the initial phase has varied. The firms set up before 1990 had to build 
new facilities/up grade facilities to meet the regulatory requirements. The firms set up 
after 1990 built facilities as per international regulatory requirements to serve 
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In the next section we will present an analysis of the motives of internationalization, entry 
into various international markets and entry strategies, products offered timings of entry, 
sequence of market entered, handicaps faced by the firms and response of sample firms in 
various markets.  We will also discuss the capabilities identified in the early phase and the 
process of building these capabilities. 
international markets. Geographically, there is a concentration in the western part of the 
country. We have one company in the Northern part and one in the South, Rest of them is 
in the western part of the country. Table 2 (a) shows the initial status. The size of firms in 
terms of turnover in 2006 ranged from Indian Rs. 70 crores to Rs. 3714 crores and their 
exports turnover ranged from Rs 20 crores to Rs 2755 crores. Present status of the firms 
with respect to physical infrastructure, products offered and number of market entered 
also varies. Table 2 (b) gives the details of their status as of 2006. By 2006 they are 
capable and well established pharmaceutical exporters. They have international standard 
manufacturing facilities with presence in multiple countries and therapeutics.  
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Products offered for 
exports in the initial 
years 




1946      1997 Aspirin
Targeted US market but first 
order executed for South East 
Asia (Bangladesh) 









Manufacturing units complying local 




1972        1983 Veterinary  products Russia
Plant complying local requirements to 














1991    1991




Plant (API and formulations) 




1994    2001
Multiple Products 




Plant matching requirements of 
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Facilities / Physical infrastructure  Presence in international 
markets  Products offered 
LSA  2.58 crores  559 crores  International standard plant  Presence in few countries 
Diversified company, products 






matching international standards 
at multiple locations and state of 
the art R & D centers 
Ground presence in 49 
countries and products sold 
in 125 countries 
Formulations and API, presence 
in multiple therapeutic segments 
PTR  138 crores  744 crores 
Plant meeting WHO-cGMP 
requirements / State of the art R 
and D centre 
Products registered in about 
50 countries 
Formulations and API, presence 
in multiple therapeutic segments 
PEL  7.73 crores  383 crores 
Production unit complying with 
international standards 
Products sold in African and 
Asian countries 







World class manufacturing for 
formulations and API, CRO 
(Clinical Research Organization) 
for clinical trials 
Ground presence in 4 
countries and sales in 46 
countries 







approved by various international 
regulatory authorities 
Selling products in about 76 
countries 







WHO-cGMP certified plant 
matching USFDA requirements 
Selling mainly into third 
world countries i.e. Africa 
and South East Asia 
Intravenous fluids and 
injectables (Large volume and 
small volume parenterals, 
respiratory, ophthalmic and 
antibiotic therapeutic segments)   IIMA  y  INDIA 
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4. Motives and Opportunities for Internationalization 
 
The motives for internationalization have varied from firm to firm. However, the most 
mentioned motive for internationalization has been to harness the opportunity to grow 
and realize higher margins in exports. The other motives have been survival in the new 
era of globalization, following the success of other Indian pharmaceutical firms in 
international markets and taking advantage of benefits given to exporters by the 
Government of India. The opportunities were created by bilateral agreement with Russia, 
enquiries for contact manufacturing by overseas buyer, opening of markets for generics 
in developed economies.  The firms which were established before 1990’s i.e. XBR, 
PTR, PEL, LSA looked at international markets to expand their operations as 
opportunities were available to export at competitive prices and obtain higher earnings 
from exports. Theses firms were operating in domestic market and when they saw 
opportunities for growth and higher margins they ventured out. While the firms set up 
after 1990’s i.e. LDC, SLC and CRM were established for international operations since 
beginning. Out of these three firms, two of the firm’s i.e. SLC and LDC top management 
had previous exposure of internationalization in the form of their association with the 
earlier firm.  Consultant associated with LSA revealed that “the firm got tempted to enter 
international market seeing success of some of the Indian companies in international 
markets”. XBR looked at international markets as opportunities to expand up to the year 
1990s and grow with higher margins in international market. The CEO of XBR in early 
1990s opined that “in the new era of globalization and product patent to be a significant 
player in the Indian market, firm must aspire to be a global player”.  PTR’s executive was 
of the view that “the opportunities for internationalization of the industry arose in the 
early 1980s were from bilateral agreement with Russia”.  The CMD of CRM shared that 
he was motivated to set up the pharmaceutical unit for exports because he observed that 
full plane loads for pharmaceutical products were exported to Russia. Incentives offered 
by government of India during those days and margins in pharmaceutical exports also 
motivated him to set up export oriented unit.  A detailing of motivations and 
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Table 3 Motivations and Opportunities of the Sample Firms 
Firm  Year of 
establishment 
Year of start of 
exports / 
internationalizing 
Motives of Internationalization 
LSA 1946  1996 
Inspiration from success of Indian firms in 
international market 
XBR 1961  1977 
Conviction of top management that to survive 
in new era of globalization firms will have to 
expand globally 
PTR 1972  1983 
Opportunities because of bilateral agreement 
with Russia for growth by expanding business 
in new territory, higher margins in international 
markets 
PEL 1982  1991 
First phase i.e. in the year 1991 and reason for 
internationalization was opportunity because of 
contact with buyer and better margins, second 
phase i.e. early 2000 saw success of other 
Indian firms in international market motivated 
firm to prepare themselves for exports 
LDC 1991  1991 
Growth and margins / had internationalization 
experience in the form of association with 
earlier firm 
SLC 1994  2001 
Opportunities for growth and margins / had 
previous exposure of internationalization / 
started afresh by setting new firm i.e. SLC 
CRM 1998  1998 
Growth and margins / motivation from quantity 
of export orders executed for Russian market by 




5. The Forays 
 
5.1 Into Markets 
 
5.1.1 The Russian Market: 
 
The then USSR provided the first opportunity to internationalize the Indian 
pharmaceutical companies. The bilateral agreement helped in the initial 
internationalization efforts. Under the Rupee-Rouble trade, pharmaceutical products, 
among other items, were exchanged between India and Russia. It softened the regulatory 
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PTR and XBR were the beneficiaries of this. The executives of PTR that entered Russia 
in 1983 explained the mode of entry as follows. 
 
In the Russian market purchasing of pharmaceutical was through centralized 
government purchases. The orders were awarded through tenders and it was more 
like public relations activity with the Ministry of Health (MOH) officials of 
Russia. 
 
This view was supported by the executive of XBR. PEL entered the Russian market 
because of contact of CMD of the firm in 1991. It received an order that took about two 
years to execute. It also was the supply to MOH. The firm got repeat orders but firm did 
not accept it as in 1993 the market was facing turmoil. 
   
5.1.2 The African and Asian Markets 
 
All the firms studied have internationalizing initiatives in African and or South East 
Asian markets. They entered these markets during the late 1980s and early 1990s. 
According to the respondents the entry was facilitated “since regulatory requirements of 
these were matching with the requirements of Indian regulatory authorities it was not 
very difficult to enter these markets”. They also concurred that the diseases were more or 
less like Indian diseases and therefore products offered in domestic market had the 
potential in Africa and Asia. Six of them entered the markets through the exports route 
while one preferred the joint ventures and partnership route. XBR executives revealed 
that it had partnership arrangement in most of the market and were selling through 
prescription route that helped them to get higher margins. They pointed out, however, 
that the marketing and administrative expenses involved in the ventures were also high. 
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Table 4 Entry into African / Asian Market 
Firms  Year of Entry  Markets Entered  Market entry strategy 
XBR 
1977, late 
1980s and early 
1990s 
Nigeria in 1977, multiple 
markets of Africa and 
Asia 
Joint Venture in Nigeria / partnership 
arrangement in African and Asian 
markets  
SLC 2001 




Started with Uganda and 




Late 1980s and 
Early 1990s 
Multiple markets of 
Africa and Asia 
Exports 
LDC Early  1990s 
Multiple markets of 
Africa and Asia  
Exports 
PEL Late  1990s 
Multiple markets of 
Africa and Asia  
Exports 
LSA  Early 2005  South Asia  Exports 
 
 
5.1.3 The Latin American, Australian, New-Zealand and South African Markets 
 
Firms clubbed Latin American market with Australia, New -Zealand and South Africa as 
in all these markets regulatory requirements were similar. They termed these markets as 
semi-regulated, as the regulatory requirements in these markets were not as liberal as in 
Africa or Asia and not as stringent as in North America. Among the seven firms studied 
only three firms i.e. XBR, PTR and SLC entered semi-regulated markets. They entered 
the market through a marketing subsidiary or acquisition.  All of them entered in 2000 or 
later. Table 4 provides the details. The reason cited by executives of the firms for such 
market entry strategy was that “these markets had very high potential and offered good 
margin for ethical generic company. To effectively sell in these markets firm should have 
a ground presence”. The discussion with executives also revealed that they targeted 
Brazil as it offered good potential for generics. We may thus note that the companies 
under study were motivated to earn more and exploited the opportunity provided by 
regulation facilitated markets through the export route. The next move to semi-regulated 
market was by a select few who saw further opportunities in semi-regulated markets. 
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Table 5 Entry into Latin American / Australia / New-Zealand / South African Markets 
Firms  Year of Entry  Markets Entered  Entry Strategy 
2000 Brazil  Marketing  subsidiary 
XBR 
2006 Italy  and  Spain Acquisition 
PTR 2003  Brazil  Marketing  subsidiary 
SLC 2003  Brazil  Marketing  subsidiary 
 
5.1.4 Entry into USA and European Markets 
 
Only two companies out of the seven studied forayed into USA and Europe. They saw 
them as highly regulated markets as regulatory requirements were stringent and very 
difficult. It required longer lead time for planning and preparation. Market entry strategy 
adopted by the firms was acquisition, marketing subsidiary or joint venture partnership. 
The firms needed a long term internationalization strategy to be in these markets. The 
executive of the XBR viewed that “Indian firms first entered into partnership agreement 
and later preferred to have wholly owned marketing subsidiary after getting exposure to 
the market”. XBR started targeting USA since 1988 as their plant got USFDA approval 
in 1988. It acquired a company in USA in 1995. It could start ethical marketing only in 
1998. It also fought and won several law suits. PTR set up a subsidiary in USA in 2006 
and got approval from USFAD for one of their plants.  
 
The foray into Europe was through the acquisition route for XBR. The executives 
mentioned that the German and French markets were in mature stage for generics and 
therefore it opted for acquisition route to enter the market faster. PTR also used the 
acquisition route to have faster entry into the German market.  2003 to 2006 was an 
active phase of internationalisation for PTR. XBR has been following a consistent well 
chalked out strategy of internationalisation.  The entry of sample firms into regulated 
markets indicates a stronger resolve to internationalise and possession of a broader base 
of resources.  Table 6 provides the details.  
Table 6 Entry into USA / Europe 
Firms  Year of entry  Entry strategy 
1995 (USA)  Acquisition 
2000 (Germany)  Acquisition 
2004 (France)  Acquisition 
XBR 
2004 (North and central Europe)  Joint Venture / partnership 
2004 (Germany)  Acquisition 
PTR 
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5.1.5 The Japanese Market 
 
The Japanese market began opening in 2005. The route choice of each firm differed, 
though it was subject to similar environmental opportunities and threats. Three 
companies from our sample were successful in foraying into this market. Two companies 
were from the Western part of the country and one was from North. On the difficulty in 
entering this market, the executive from LDC remarked, “Guidelines to enter Japanese 
market were not available till 2005. It was a closed and non-transparent market. It has 
started opening up since 2005”. LDC chose exports; XBR chose joint venture while PTR 
opted for setting up a marketing subsidiary.  Table 7 provides the details.  
 
Table 7 Entry into Japan 
Firms  Year of entry  Entry strategy 
XBR 2005 Joint  Venture 
LDC 2005  Exports 
PTR 2006  Subsidiary 
 
It may be observed from the experience presented above that the internationalization 
phase of Indian Pharmaceutical companies started with less regulated markets like Africa, 
South East Asia in late 80’s and early 90’s because of increasing opportunities and the 
necessary competitive advantage and matching guidelines that of India. During late 90’s 
the firms started looking at Latin America, Australia and New Zealand and South African 
markets owing to experiential learning from Africa and Asia Pacific markets, 
competitiveness and globalization. The next target markets for Indian firms were USA 
and Europe. Indian pharmaceutical companies started targeting Japanese market from the 
year 2005 as the regulatory authorities of Japan become open to foreign companies and 
relaxed the regulatory requirement. Table 8 provides the summarized sequence of 
markets entered for internationalisation.  
Table 8 Sequence of International Markets Entered 
Firms  Sequence of markets entered 
LSA  Targeted US market but first order executed for South East Asia (Bangladesh)
XBR  Africa-Asia-USA –Europe and Latin America-Japan 
PTR Russia-  Africa-Asia-Brazil-Germany-USA-Japan 
PEL  Russia-Africa and Asia 
LDC Africa-Asia-Japan 
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The Indian companies entered international markets in the sequence i.e. Russia- Africa-
Asia-Pacific- Latin-America, Australia, New-Zealand and South Africa –USA and 
Europe –Japan. The regulatory requirements also increase in the same order sequentially. 
The requirements in African markets and some of the South East Asian markets were 
matching the requirements of Indian authorities therefore it was not much difficult to 
enter these markets. The early phase internationalization started with Russian, African 
and some of the Asia-pacific markets. Later during late 90’s the firms started looking at 
Latin America, Australia and New Zealand and South African markets. In early 2000 
most of the firms started preparing to enter USA and European markets. XBR targeted 
USA market as they found that to grow faster it is important to target one of the biggest 
markets of the world, while firm PTR targeted Latin American market i.e. Brazil as they 
found that it easier in terms of regulatory requirements to enter Brazil compare to USA. 
Firm XBR instead of moving from less regulated to highly regulated market, moved 
straight to highly regulated market USA and then entered Brazil i.e. semi-regulated 
market.  XBR had a clearer internationalizing strategy. It had articulated its motivation as 
being a part of the global industry and the top management of the company was 
committed to it. Others reacted to an opportunity provided by the market or followed the 
success of players in the industry. Once in, they moved on to act with a strategy. The 
firms established before 1990 started targeting international markets in early 1990s. The 
firms which were established after 1990’s i.e. SLC and CRM looked at various markets 
simultaneously as they were set up to cater to international markets with all required 
resources in terms of physical infrastructure to cater to various international markets. 
They leveraged on the experience of the industry and set up their practices as per the 
international regulatory requirements.   
 
5.2 Products for the markets 
 
While the sample firms attacked similar markets, did they offer the same product? Did 
they focus on the same therapeutic area? Did they offer whatever they were making in the 
domestic market?  The discussion with executives of the firms reveals that most of them 
started with their existing product portfolio to enter international markets. Since the local 
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firms were not required to develop specialized products to enter international markets. 
Once the firm got a foothold in the specific foreign market, it started developing products 
specifically for foreign markets. Most of the firms developed products going off patent in 
foreign markets. PEL and PTR developed products specifically to sell in Russia. 
Veterinary products were not the main line of business for PTR; however, it developed 
the product to serve international markets. In Africa and South East Asia, it extended its 
range of cardiovascular, neurological and respiratory therapeutic segment related 
products. Later it also started developing off patent products. Similarly, PEL also 
developed the product DENOL especially for Russian market. It was not very difficult to 
get product quality approval as the Government of India had bilateral agreement with 
Russian government. PEL’s next strategy was to enter into a licensing agreement to 
manufacture and sell the products of licensee in domestic and some of the foreign 
markets. They have entered into number of licensing agreements to manufacture and sell 
products with innovators. The CMD of the firm is of the view that “it is not possible to 
match the quality of innovator’s product. They followed a philosophy to never violate the 
product patent; therefore they entered into licensing agreement”. 
 
LDC and CRM developed products for contract manufacturing with foreign buyers and 
buyers in India for export markets respectively.  LDC’s experience can be captured as 
follows:   
 
It entered into an agreement which included product development and sales in 
foreign market with the conract manufacturer. The development expenses were to 
be borne by the foreign party which wanted LDC to develop the product. The 
foreign player also agreed to purchase the product from LDC up to certain time 
period and of certain quantity.  
 
The executive of LDC viewed that this was a risk free model to enter international 
markets. Since Indian firms had competitive advantage in terms of product development 
and manufacturing cost such opportunities were available in international markets. To 
identify such buyers, the firm looked at large distributors of generic products in the 
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referring directories. CRM started with Large Volume Parenterals (LVP), a simple and 
common product with potential in domestic as well as international markets. CRM learnt 
the requirements of international market from other Indian firms that entered into contract 
manufacturing agreements. Once in the market, the Indian pharmaceutical firms that were 
into exports of formulations got enquiries for injectables. Such firms passed on the 
enquiry to CRM. Later on it ventured into specialized products i.e. ophthalmic and 
respiratory range of Small Volume Parenterals (SVP). The executives of XBR and SLC 
viewed that “since new product development is costly and time consuming most of the 
Indian firms identify products going off patent in near future and start developing it so 
that on day one of product becoming generic the company can launch it in the 
international markets”. SLC started with a range of products which could be offered in 
both the markets as its promoters and employees had previous experience in 
internationalization. To LSA, a diversified company, it was a question of selling its 
products manufactured from raw material of a by product profitably. They were selling 
this product in the domestic market. They needed to develop a specific grade of this 
product to sell in international markets.  After trial and error they succeeded in 
developing the desired product and export. Table 9 provides the details of the products 
offered by the sample firms in different markets. We may note the wide range of 
therapeutic segments targeted by the companies. The target therapeutic segment differs 
from country to country and firm to firm. The range is the widest for Brazil. Thus we 
may see that as an industry, the Indian pharmaceutical industry has a much diversified 
market, product and therapeutic scope. What were the capability handicaps and the 
responses of the firms that enabled them to reach the current state of progress? The next 
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Table 9 Products Offered in the Early Phase of Internationalization: 
Firms  Markets  Products offered 
Targeted US market 
but first order 
executed for South 
East Asia 
(Bangladesh) 
Analgesic therapeutic segment(Aspirin) 
LSA 
USA  Analgesic therapeutic segment (Aspirin) 
Africa  Anti-infective, Anti-viral segment  
Asia  Anti-infective, Anti-inflammatory and Anti-viral segment 
USA and Europe 
Anti-infective, Anti-viral, Anti-inflammatory, 
Cardiovascular, Anti-diabetic segment 
Latin America  As Above 
XBR 
Japan As  Above 
Russia Veterinary  products 
Africa  Ant-infective and Anti-inflammatory segment 
Asia 
Central Nervous System (CNS), cardiovascular, anti-
infective, anti-diabetic, Rejuvenator etc. 
Brazil As  above 
Germany and USA  As above 
PTR 
Japan - 
Russia  DENOL (Anti-Ulcer / Anti-bacterial) 
Africa 
Anti- infective, Multi Vitamin, Dietary supplement, 
consumer and cosmetics 
PEL 
Asia As  above 
Africa 
Anti-infective, Anti-diabetic, Anti-inflammatory, 
Cardiovascular   
Asia As  above 
LDC 
Japan  Bulk Drugs (Anti-infective) 
Africa 
Large volume common solutions, electrolytes, 
Antibacterial,  
Asia 
Large volume common solutions, electrolytes, 
Antibacterial, Anesthesia, blood products, plasma volume 
expanders and Diuretics 
Brazil 
Large volume common solutions, electrolytes, 
Antibacterial, Anesthesia, blood products, plasma volume 
expanders, Enteral and Parenteral Nutrition, Renal & 
Transplant, Oncology, Infusion Therapy and Diuretics etc. 
SLC 
South Africa  As above 
Africa 
Large volume parenterals, Electrolytes and common 
solutions / Anti bacterial) 
CRM 
Asia 
Large volume parenterals (Electrolytes) as well as Small 
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6. The Capability Handicaps and Responses 
 
6.1 The capability Gaps 
 
In realizing their motivation and entering multiple markets with multiple target 
therapeutic segments and products, the sample firms faced multiple handicaps relating to 
regulation, quality, logistics and talents. Responding to handicaps in one did not resolve 
the handicaps in another automatically. The firms had to pay deliberate attention to each 
market requirement and respond accordingly. As a consequence, each market entry built 
its own portfolio of capabilities.  
 
The handicaps were capabilities to understand and respond to the requirements of World 
Health Organization-current Good Manufacturing Practices (WHO-cGMP), USFDA, 
international manufacturing practices, quality assurance and quality control, product 
registration, market seeding and development, logistics for international market, 
sourcing, legal knowledge of intellectual property (IP) rights, and the country conditions.  
Entry to the Russian market was facilitated by the bilateral agreement, but the firms had 
to develop capabilities in tendering and winning the tenders on competitive pricing.  
 
6. 2 Firm Responses 
 
6.2.1 Responding to Regulatory Requirements 
 
The early internationalisers in the pharmaceutical industry had to first build the 
knowledge of the regulatory requirements of various markets and then devise ways of 
responding to them. They had the option of in-house initiation through trial and error or 
of hiring an experienced executive and empowering him to develop the capabilities either 
through new hire or through internal training. The later internationalisers could leverage 
on the experience of the industry and develop their capabilities. The regulatory 
requirements of various countries were in the public domain and could be obtained from 
regulatory authorities of respective countries. The firms needed the help of technical and 
legal experts to comprehend the nuances of the regulations. XBR and PTR which 
ventured into international markets early could not get experienced professionals. 
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foreign markets and developing rapport with officials of regulatory authorities. Based on 
dossiers submitted to regulatory authorities, authorities gave their comments / raised 
queries. These queries were replied by taking the help from officials of authorities and 
local partner. In case of plant approval, authorities visited the plant and guided the firm 
executives to take appropriate actions for meeting the requirements. Other firms (LDC, 
PEL, CRM, LSA) recruited experienced hands as they could get them from Indian 
companies which started early and developed in-house capability.  Later PTR hired an 
international consultant to enter the Latin American market.  XBR continued to learn 
through trial and error by giving freedom to its employees to learn and implement 
decisions. It hired international legal experts and developed a full fledged IP cell in the 
company with employees having legal and domain knowledge. Firms organized in-house 
training programmes to develop regulatory competency among other employees. The 
employees were deputed to attend seminars / workshops / conferences so that they could 
update themselves about changes in regulatory requirements.   
 
XBR and PTR were helped by the bilateral agreement in entering Russia. The already 
developed manufacturing capabilities in the domestic sector were leveraged to respond to 
the requirements of the first order. They used this exposure to make further entry into 
other international market. PEL also benefited from the Russian regime, but they incurred 
heavy losses from exports to Russia as USSR got disintegrated at the time of their entry. 
The company then became conservative and focused on domestic markets. It then 
became aggressive only during early 2000. The later internationalisers CRM and SLC 
were able to leverage on the Indian exporting experience, hired experienced professionals 
from India to meet the regulatory requirements. CRM recruited second –in-command 
experienced person from already internationalized firms and made him in-charge of the 
internationalization initiatives. Therefore they could start as day one internationalizers.  
The promoters of SLC had earlier promoted another pharmaceutical company that had 
exported significantly. They were familiar with the regulations and characteristics of 
various markets.  Table 10 provides the details of the handicaps faced by the sample 
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Table   10 Handicaps and Responses in Various Markets 




Environmental support in the form of Bi-lateral 
agreement with Russian government helped 









Firm PTR hired international consultant / firm 
XBR and SLC learned on their own through 
trial and error   
USA and 
Europe 
USFDA / IP knowledge / 
Internationalization 
knowledge 
Up graded plant to USFDA requirements / hired 
international consultants for IP and developed 
IP cell in the firm 
Japan 
Non availability of 
guidelines 
Japanese government opened up the market 
 
Table 11   Firm wise Handicaps and Responses 




-Hired person having experience of international 
markets 
XBR 




Rights (IPR)  
-Gave freedom to their employees to learn through 
trial and error 
-Hired international lawyers / set up IP cell in the 





-infrastructure Facilities  
-Hired international consultants / developed 
employees to learn through trial and error 
-Up graded existing plant / allocated separate plant 









-WHO-cGMP / USFDA 
plant facilities 
-Hired experienced persons 
-Up graded plant facilities to meet WHO-cGMP 
requirements / Set up new plants meeting USFDA 
requirements 
SLC 
-Image of an Indian 




-Invited officials of regulatory authorities to visit the 
plant and entered into technical dialogues with them 
-Top management of the firm had experience of 







-Hired person with experience of internationalization 
in various functional areas 
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6.2.2 Plant Up gradations 
 
The firms up graded or set up new plant facilities to respond to the requirements of 
WHO-cGMP / USFDA. They invited officials and consultants to visit the plants prior to 
the final inspection. They learnt from the inspection reports that provided guidelines for 
improvement and removing the credibility gaps. An SLC executive opined, “If officials 
of regulatory authorities are invited to visit the plant before plant approval application is 
submitted, it would help in removing the bugs earlier. He also opined that entering into 
technical discussion with the officials of regulatory authority helped firms to build 
credibility”. Executive of CRM is of the view that “relationship with the regulatory 
authorities helps in getting faster responses for queries and right guidance to comply with 
the queries”. The relationship was developed by inviting them to visit manufacturing 
plant and by responding to queries faster. 
 
6.2.3 Developing Complementing Functional Capabilities 
 
Firms which started early i.e. XBR and PTR offered entrepreneurial culture to employees 
for developing specialized capabilities for various functional areas. Others offered higher 
remuneration to attract and retain experienced manpower for internationalization. LDC 
organized training programs throughout the year for employees involved in international 
market operations. To manage quality assurance and control, the firms developed 
standard operating procedures for each and ever activity starting from purchase of inputs 
to delivery of products to customer. Training programs were organized to help the 
employees to understand the procedures and responding to the instructions consistently.  
The executive of LDC mentioned, “For international markets quality is critical, therefore 
we organize training programs related to quality for all the employees across 
organization”. The Executive of CRM informed, “To update its knowledge we subscribe 
to various journals wherein some of the articles give hint about future changes. Based on 
the hints we start preparing for such changes and appraise all the concerned employees 
through in-house training programs”.  
 
Production capability of the firms is related to setting up WHO-cGMP / USFDA 
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varying specifications. Since Indian firms were producing products for the local market, 
the capability was well developed to manufacture multiple products. Production planning 
was managed by clubbing small orders from different buyers based in various foreign 
markets. Firms like LDC, XBR, PTR, and PEL have set up supply chain management 
departments to manage this function. XBR and LDC used enterprise resource planning 
software i.e. SAP for production planning. Over a period of time all the firms had internal 
audit teams for QA and QC auditing. Non compliances reported by the audit teams are 
addressed suitably. In responding to the functional capability requirements the firms 
benefited from the overall manufacturing culture in the country, the network of publicly 
funded research and development laboratories and an extensive network of educational 
institutions imparting higher education in engineering and sciences.   
  
Procurement was another area needing attention. The Firms were able to develop this 
over a period of time through experience. The sources of suppliers were identified with 
the help of databases (directories) of suppliers, internet, references / leads from existing 
suppliers, participating in trade fairs / seminars / conferences etc.   
 
Table 12 shows types of capabilities required and the processes adopted by the firms to 
develop the capabilities.  
 
Table 12 Types of Capabilities Required / Developed and Outcome of Capability 
Type of 







-Identifying and selecting markets, 
products, distributors/agents, entry 
strategy for international market 
development 
-Product launch and promotion in 
international markets 
-Getting orders and delivering the 
products in time 
-Recruited experience employees 
-Developed own employees 
capabilities by trial and error 
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-Understanding regulatory requirements 
related to plant approval and product 
registration 
-Getting plant approval from various 
regulatory authorities i.e. MOH of 
respective country’s Government 
-Getting product registration from MOH 
of various countries which are targeted 
by the company  
-Through experienced hands and 
consultants 
-Employees learnt through trial and 
error 
-Sought guidance from regulatory 
authorities and foreign partner i.e. 
agent 
-Training to employees by sending 
them to attend seminars, conferences, 
training programmes 
-In-house training programmes 
QA / QC 
Capability 
-Knowing pharmacopeia requirements, 
customer requirements and setting 
company’s own standards 
-Complying with QA / QC requirements 
of regulatory authorities 
-Help in R and D and preparation of 
dossiers for plant approvals and product 
registration 
-Quality control and offering consistent 
quality 
-Experienced persons, fresher can also 
understand pharmacopeias and other 
related requirements 
-develop Standard Operating 
Procedures (SOP’s) 
-Training to all across organization for 
quality requirements of international 
markets 
-Internal auditing 
-Subscribing related journals to 





-Sourcing machinery, equipment , raw 
material and packaging material at most 
competitive prices and complying the 
requirements of international markets 
-Timely delivery and consistent quality 
of input materials  
-Database of suppliers / internet / lead 
from existing suppliers 
-Sending executives to attend trade 
fairs / seminars / conferences 




-Ability of firm to recruit, motivate, 
train and retain qualified and 
experienced manpower 
-Ability to update the manpower for 
changing requirements  
-As all functional area (regulatory, QA 
and QC, market development, 
production and production planning, 
purchasing and procurement, R and D, 
finance) needs manpower who can 
understand requirements of international 
markets 
-Opportunities to make career in 
international business function to 
freshers 
-Freedom for decision making / 
entrepreneurial culture 
-Deputing employees for training / 
seminars / conferences 
-Attracting potential employees by 
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-Capability to manufacture multiple 
products for multiple markets with 
varying specifications 
-Production planning for small order 
quantity and complying with the GMP 
requirements of minimum batch size 
-Timely delivery of products to 
customers with lower inventory cost  
-WHO-cGMP / USFDA plant 
-Supply chain management 
department 
-Implementing ERP software 
R and D 
Capability 
-R and D capability for processes and 
QC 
-Capability for Generic product 
development, NDDS and NCEs 
-R and D for generating clinical trials 
and other data for dossier preparation 
-Recruiting talented scientist 
-Collaboration with university 
departments and other scientific 
laboratories 
-Setting up of CRO for clinical trials 
Finance 
Capability 
-Higher financial requirements for 
USFDA / WHO-cGMP plant 
-Finance capability for market 
development and product registration 
expenses 
-Internal funds 
-Term loans from banks 
-Firms uses capital budgeting and 
revenue budgeting  
 
 
7. Implications for Further Research  
 
 
In the above sections we presented the experiences of sample firms in committing 
themselves to internationalization of their pharmaceutical businesses and developing the 
needed capabilities through experts’ help and own trials and errors.  The firms moved 
from a less regulated setting to a more regulated setting. The capabilities built in one 
were not necessarily resolving the issues of the other. The firms needed to apply 
themselves afresh. What facilitated the march forward was the strengthening of the 
motive commitment to internationalize and the learning capability of the old and new 
employees. The firms also learnt from inspections by and interaction with regulatory 
authorities. We have built further to look at various capability gaps and processes by 
which the firms respond to these gaps. We have also looked at facilitators in terms of 
overall industry, country and international experience. The later internationalizes were 
able to leverage on all these while the early internationalisers had to depend on 
international expertise and non pharma country experience. They benefited from the 
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environment in aiding capability building is an under explored area. There is scope for 
research in this direction.  
 
Our study has examined the experiences of two types of internationalisers – early 
internationalisers and later internationalisers in the Indian pharmaceutical industry.  The 
early internationalisers have followed stage theory while the others did not follow stage 
theory. The early internationalisers support Chang (1995), and Ahuja and Katila (2004) 
who have argued that internationalization capabilities could be built through sequential 
entry.  The later internationalisers could attack multiple markets on the strength of their 
abilities to congregate capabilities from the industry and outside. Congregation demands 
negotiating and co-ordinating capabilities. This aspect of congregating capabilities for 
formulating and implementing strategies has not been discussed adequately in the 
literature. There is literature on organizational learning that focuses on firms attempt to 
cultivate capabilities within. There is scope for further work. An efficient and effective 
congregation increases the speed, scope and spread of a firm’s activities.  
 
Researches on internationalization have shown that the reasons for increase in 
international activities are global competition, reduction in trade barriers and improved 
communication and information network. This research identifies that since Indian 
pharmaceutical industry had competitive advantage in terms of cost and there were 
opportunities to sell in international markets, industry could internationalize its 
operations. The motives of Indian pharmaceutical firms in early phase for 
internationalization of business were growth, expansion of activities and higher earnings 
through export sales which confirms to the findings of earlier researchers. The early 
internationalizing firms which were set up before 1990s, had motive to expand their 
business through exports. Firms which were set up after 1990s were specifically set up to 
cater to international market as they had knowledge that Indian companies are successful 
in international markets, therefore they wanted to exploit the opportunities. 
 
Researchers have identified lack of resources, skills and knowledge for initiating exports 




Page No. 29  W.P.  No.  2008-02-05   IIMA  y  INDIA 
Research and Publications 
how firms can overcome these barriers. The responses depend on the motivations of the 
firm and its initial commitments.  
 
The facilitators to overcome barriers identified by researchers are superior products and 
service quality, technical knowledge for initiating exports and top management 
commitment, bundling and leveraging resources of firms. Other ways, researches have 
shown are entrepreneurial management, flexibility, responsiveness to change and 
innovations. This research identifies the contribution of top management commitment, 
consultants and agents in foreign markets, experienced staff, and bilateral agreement with 
Russia as facilitators in early phase. The barriers were also overcome by encouraging 
own people to learn about market requirements. There is scope for integrating this 
further.  
 
The criteria to select market in early phase of internationalization as identified by the 
researchers are psychic and geographical distance from home market, culture, local skills, 
social and political status of country, host government policies and previous experience 
with the country. This research identifies another dimension within host country 
government policies i.e. regulatory requirements of Ministry of Health (MOH) of host 
country. Acceptance of generics and Indian products in foreign market is also one of the 
criteria to select the market. Firms start with the markets in which regulatory 
requirements are more or less similar to Indian regulatory requirements, which firms can 
match easily. This is a unique dimension of internationalization in the emerging 
economies.  We should also recognize that the early regulatory regime of the emerging 
countries build certain capabilities in the country and the companies participating in the 
economic activities of the country. The firms were able to leverage on them as they faced 
capability handicaps.  This link between capabilities then, capabilities for 
internationalization now and those in future needs to be studied.  
 
This research also confirms the findings of earlier researches related to selection of 
products in the early phase of internationalization wherein most of the firms select similar 
products as offered in domestic markets, basic and common products in terms of 
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aspect of the research which is understudied. As an entry strategy itself some firms 
developed products that were not a part of the current portfolio in the domestic market. 
The attraction here was the margins that would be gained and the new experience that 
could be leveraged to sell the current products. As the firms gained experience, they 
dreamt of developing products for international markets in anticipation.  This is another 
unique aspect of some firms in the emerging sector. They would like to associate 
themselves with products in demand in the developed economies to earn higher margins 
and develop cutting edge capabilities.  This is another area worth researching.  
 
We also highlighted the specialized nature of the capabilities of the sector. The nature is 
specialized because of knowledge intensive characteristics of industry. Most of the 
functional area capabilities require distinct knowledge bases. It is also found that few of 
the capabilities are interrelated and they are required to be developed simultaneously. 
Research required here is the attention to simultaneity.  We need to confirm and 
consolidate our findings by conducting research for other sectors in the emerging 




In this paper we identified and analyzed the morivation, capability handicaps and 
responses of a sample of Indian Pharmaceutical firms in the early phase of 
internationalization. We argued that this phase marked several discontinuities for the 
firms engaged in meeting the needs of domestic market. The managerial anxieties in this 
context arise from the motivations to internationalize and capability handicaps that delay 
their realization. The challenges identified were meeting the regulatory requirements, 
gaining customer acceptance, enlisting support from domestic operations. The decisions 
to be made related to goals of internationalization, market to enter, mode of entry, 
acquisition and development of capabilities to respond to entry requirements. The stimuli 
for internationalization were identified as opportunities for higher margins, market 
diversification, and survival in view of global competition. The capability handicaps of 
the firms were regulatory compliance, international plant management practices, quality 
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responded to the handicaps by congregating capabilities from outside and cultivating 
some through trial and error. Top management commitment to the motivation to 
internationalise and employee empowerment played a key role in building the needed 
capabilities. It integrated the insights from in depth studies of internationalization 
experience of six pharmaceutical companies and one quick study. It identified the scope 
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